Rounds
Nouscom raises €120M Series D to fund pivotal immunotherapy trial
The Swiss biotech plans to advance its lead therapy into a global registration study targeting Lynch Syndrome.
Topic
Later-stage rounds (Series B and beyond) and large growth financings.
The Swiss biotech plans to advance its lead therapy into a global registration study targeting Lynch Syndrome.
The Indian apparel maker plans to expand from 25 to 150 retail stores and broaden its menswear catalog.
Rounds, investors and deadlines that matter. Daily, 5-minute read. Unsubscribe anytime.